



INDO-BANGLA PHARMACEUTICALS LIMITED

PLOT # 183 (7th FLOOR), BLOCK # B, AHMED AKBER SOBHAN ROAD,
BASHUNDHARA R/A, Dhaka-1229.

PRICE SENSITIVE INFORMATION

This is for kind information that the Board of Directors of Indo-Bangla Pharmaceuticals Limited in its 59th meeting held on Sunday 30th January, 2022 at 3:00 p.m. at the corporate office, has approved the Un-Audited Financial Statements for the Second Quarter (Q2) period ended on 31th December, 2021.

The key financial highlights for the Second Quarter ended 31th December, 2021 are appended below:

Particulars	As at 31.12.2021	As at 30.06.2021
Net Asset Value (NAV) Per Share	Tk. 14.58	Tk. 14.29

Particulars	July to December 2021	July to December 2020	October to December 2021	October to December 2020
Earnings Per Share (EPS)	Tk. 0.51	Tk. 0.66	Tk. 0.18	Tk.0.33
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.41	Tk. 0.68	-	-

By order of the Board of Directors

-sd-

(Mohi Uddin QCS)
Company Secretary

The details of the published Second Quarter (Q2) Financial Statements are available in the website of the company: www.indo-banglapharma.com.